Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 15 of 23
Apr 1, 2026By acquiring Centessa Pharmaceuticals, Eli Lilly gains access to cleminorexton, an orexin agonist drug candidate that may revolutionize treatment for narcolepsy and other sleep disorders. This move aligns Lilly with other leading pharmaceutical companies developing innovative therapies in sleep science.
Michael Torres
Mar 31, 2026In a significant biopharmaceutical industry move, Biogen announced its acquisition of Apellis Pharmaceuticals for $5.6 billion upfront. This acquisition aims to bolster Biogen’s presence in immunology, a critical and growing therapeutic area with unmet medical needs.
Daniel Cho
Mar 31, 2026Takeda, a leading global biopharmaceutical company, is undergoing restructuring including significant job cuts in Massachusetts. This move aligns with strategic shifts to support product launches and operational efficiency amid evolving industry challenges.
Dr. Priya Nandakumar
Mar 30, 2026The recent market launch of Icotyde by Johnson & Johnson has sparked renewed competition in psoriasis therapeutics. However, analysts and stakeholders remain confident about Skyrizi's efficacy and dosing advantages, presenting a compelling narrative for patients and clinicians alike.
Sophia Reynolds
Mar 25, 2026Seeking to bolster its pipeline with innovative cancer treatments, Merck has announced its intent to acquire Terns Pharmaceuticals for $6.7 billion. This deal prioritizes a promising leukemia drug candidate, aiming to enhance treatment options for patients affected by this challenging disease.
Jonathan Blake
Mar 25, 2026The pharmaceutical industry is undergoing significant shifts in research and development spending. In 2025, the top 16 largest companies spent a total of $159 billion on R&D, marking a 3.6% decrease from $165 billion the previous year. This change reflects evolving priorities and strategic decisions about which programs to advance amidst a competitive and financially challenging environment.
Jonathan Blake
Mar 25, 2026The $1.7 billion acquisition of Ouro Medicines by Gilead Sciences marks a significant advancement in the quest to address autoimmune conditions through immune system modulation. The collaboration with Galapagos heralds a potential new phase in drug development focused on resetting immune responses.
Dr. Priya Nandakumar
Mar 24, 2026Despite punitive measures levied against pharmaceutical companies over alleged kickback schemes, these penalties constitute a small fraction of revenues and have not significantly dented companies' bottom lines. This post explores the implications of these findings on regulatory efficacy and industry practices.
Sophia Reynolds
Mar 24, 2026The pandemic has reshaped biotech funding in ways that many may not recognize at first glance. Companies eager for a rebound must instead adapt to the new environment, recalibrating strategies and expectations in order to thrive.
Daniel Cho
Mar 24, 2026Despite already marketing a PI3Kα inhibitor, Novartis is acquiring an early clinical asset from Synnovation Therapeutics, seeking a potentially best-in-class next-generation therapy for breast cancer. This move reflects intense competition and strategic portfolio expansion in oncology.
Dr. Priya Nandakumar
Mar 21, 2026Providence announced its intent to sell its health plan, moving away from the combined payer-provider model known as the 'payvider' strategy. This development reflects broader industry trends, where health systems are reconsidering their role as insurers due to mounting financial pressures and operational complexities. The sale underscores a shift toward focusing on core healthcare delivery and exploring collaboration with established payers rather than direct insurance operation.
Dr. Alex Morgan
Mar 20, 2026Imcivree’s approval opens the door to a potentially lucrative market in rare obesity treatment, with sales projections exceeding $2 billion globally. Despite past phase 3 trial failures, the drug’s regulatory success highlights the evolving landscape for rare disease therapeutics.
Emily CarterMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.